Advertisement

 

 

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.
Author Information (click to view)

Lin YH, Liao XN, Fan LL, Qu YJ, Cheng DY, Shi YH,


Lin YH, Liao XN, Fan LL, Qu YJ, Cheng DY, Shi YH, (click to view)

Lin YH, Liao XN, Fan LL, Qu YJ, Cheng DY, Shi YH,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2017 08 2312(8) e0183300 doi 10.1371/journal.pone.0183300
Abstract
BACKGROUND
The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted.

METHODS
Eligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug twice daily (group II), Bud/Form 320/9ug twice daily (group III), or Tio 18ug once daily with Bud/Form 160/4.5ug twice daily (group IV) for 6 months. Systemic inflammation biomarkers were measured before randomization and during the treatment, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α), fibrinogen (Fib), and white blood cell (WBC).

RESULTS
After 6-month treatment, CRP levels in group II, group III and group IV changed by a median (interquartile range) of -1.25 (-3.29, 1.18) mg/L, -1.13 (-2.55, 0.77) mg/L, and -1.56 (-4.64, 0.22) mg/L respectively, all of which with statistical differences compared with group I. In addition, there were no treatment differences in terms of IL-8, SAA, TNF-α, Fib and WBC levels.

CONCLUSIONS
A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone.

Submit a Comment

Your email address will not be published. Required fields are marked *

19 − fifteen =

[ HIDE/SHOW ]